These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21247151)

  • 1. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
    Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
    Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
    Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
    Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
    Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.
    Shi J; Fan D; Dong C; Liu H; Jia B; Zhao H; Jin X; Liu Z; Li F; Wang F
    Theranostics; 2014; 4(3):256-66. PubMed ID: 24505234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation.
    Janssen M; Frielink C; Dijkgraaf I; Oyen W; Edwards DS; Liu S; Rajopadhye M; Massuger L; Corstens F; Boerman O
    Cancer Biother Radiopharm; 2004 Aug; 19(4):399-404. PubMed ID: 15453954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.
    Shi J; Kim YS; Zhai S; Liu Z; Chen X; Liu S
    Bioconjug Chem; 2009 Apr; 20(4):750-9. PubMed ID: 19320477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.
    Li ZB; Chen K; Chen X
    Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1100-8. PubMed ID: 18204838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
    Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
    Cai W; Chen K; Li ZB; Gambhir SS; Chen X
    J Nucl Med; 2007 Nov; 48(11):1862-70. PubMed ID: 17942800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
    Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
    Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
    Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
    Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
    Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S
    Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.
    Bozon-Petitprin A; Bacot S; Gauchez AS; Ahmadi M; Bourre JC; Marti-Batlle D; Perret P; Broisat A; Riou LM; Claron M; Boturyn D; Fagret D; Ghezzi C; Vuillez JP
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):252-63. PubMed ID: 25164771
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.